| Title: AtheroGenics and AstraZeneca Win Best Partnership Alliance of the Year at Annual Scrip Awards |
Date: 11/17/2006
|
11/16/2006
AtheroGenics and AstraZeneca Win Best Partnership Alliance of the Year at Annual Scrip Awards
ATLANTA, GA -- (MARKET WIRE) -- 11/16/2006 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced winning the "Best Partnership Alliance of the Year" award with AstraZeneca at the Annual Scrip Awards Dinner on Wednesday, November 15, 2006 at the Grosvenor House in London, England.
This international partnership alliance award is in recognition of AtheroGenics' collaboration with AstraZeneca to develop and commercialize AGI-1067 for coronary artery disease.
"We are honored to receive this award, which recognizes the significance of the alliance formed between AstraZeneca and AtheroGenics to bring forward what we both hope will be an important new drug for the treatment of heart disease," said Russell M. Medford, M.D., Ph.D., President and CEO of AtheroGenics, Inc.
The Annual Scrip Awards were developed by the editorial team at Scrip and industry leaders to recognize and celebrate excellence in the pharmaceutical and biotechnology industries globally.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit www.atherogenics.com
|
